文献速递药物不良反应与药物警戒

中国药物警戒体系的演变与未来挑战

Pharmacovigilance in China: Evolution and future challenges.
PubMed 文献 · Br J Clin Pharmacol · 2022-03-16

本文概述中国自2019年正式实施药物警戒体系以来的发展,指出自发报告系统是主要数据来源但证据强度不足以支持监管决策,并分析MAH能力建设、医学教育缺失等问题及监管部门的应对措施。

要点

  • 中国2019年正式实施药物警戒体系,配套质量管理规范及技术文件。
  • 自发报告系统是主要数据来源,但证据不足以支持监管决策。
  • 监管部门通过行动计划、患者报告和主动监测系统提升药物警戒能力。

核心结论

  • 中国药物警戒体系已正式建立并运行,但仍面临证据强度不足、专业人员能力欠缺等挑战。
  • 监管部门已采取措施提升药物警戒专业能力并加强利益相关方合作。

研究设计与样本

  • 本文为综述,总结中国药物警戒体系从药品不良反应报告系统到药物警戒体系的演变及未来挑战。

主要发现

  • 自发报告系统是中国药物警戒活动的主要数据来源,但未能为监管决策提供足够强有力的证据。
  • 中国政府加快急需临床药物和孤儿药审批,同时要求加强上市后安全监管。
  • 上市许可持有人(MAH)作为药品安全第一责任主体需加强药物警戒能力。
  • 中国医学院校普遍缺乏药物警戒专业课程。

临床怎么用

  • 临床药学人员应关注自发报告系统的局限性,结合主动监测系统数据评估药品安全性。
  • MAH需落实药物警戒主体责任,加强上市后安全监测与风险控制。

局限性

  • 本文为综述性文章,未报告原始研究数据或定量分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-related adverse reactions are among the main reasons for harm to patients under care worldwide and even their deaths. The pharmacovigilance system has been proven to be an effective method of avoiding or alleviating such adverse events. In 2019, after two decades of implementation of the drug-related adverse reaction reporting system, China formally implemented a pharmacovigilance system with the Pharmacovigilance Quality Management Standards and a series of supporting technical documents created to improve the safety of medication given to patients. China's pharmacovigilance system has faced many problems and challenges during its implementation. This spontaneous reporting system is the main source of data for China's medication vigilance activities, but it has not provided sufficiently powerful evidence for regulatory decision-making. In conformity with the health-centred drug regulatory concept, the Chinese government has accelerated the speed of examination and approval of urgently needed clinical drugs and orphan drugs along with the requirement to improve the safety supervision of these drugs after their listing. China's marketing authorization holders (MAHs) must strengthen their pharmacovigilance capabilities as the primary responsible departments for drug safety. Chinese medical schools generally lack professional courses on pharmacovigilance. The regulatory authorities have recognized such problems and have made efforts to improve the professional capacity of pharmacovigilance personnel and to strengthen cooperation with stakeholders through the implementation of an action plan of medication surveillance and the establishment of a patient-based adverse events reporting system and active surveillance systems, which will help China bridge the gap to bring its pharmacovigilance practice up to standards.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Song H, Pei X, Liu Z, et al. Pharmacovigilance in China: Evolution and future challenges. Br J Clin Pharmacol. 2022. PMID: 35165914. doi:10.1111/bcp.15277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。